×

Active Biotech AB Interim report January - September 2015

LUND, Sweden, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Laquinimod

  • The pivotal CONCERTO clinical Phase 3 study in relapsing remitting MS (RRMS) is proceeding according to plan and results are expected in 2017
  • The Phase 2 studies, ARPEGGIO, which will evaluate laquinimod's potential for treatment of primary progressive MS (PPMS), and LEGATO-HD, for the treatment of Huntington's disease, are proceeding as planned

Tasquinimod

  • The final results from Active Biotech's tasquinimod 10TASQ10 Phase 3 trial were presented at the ECC conference and demonstrated that while tasquinimod treatment resulted in a prolonged radiographic progression-free survival (rPFS), 7.0 vs. 4.4 months, the positive effect on rPFS did not translate into an improved OS

ISI

  • Only commercial activities will be conducted from 2016

Financial summary

MSEK July - Sept. Jan. - Sept. Jan. - Dec.
2015 2014 2015 2014 2014
Net sales 5.2 2.6 11.3 7.5 10.4
Operating loss -22.2 -55.7 -149.7 -172.8 -228.5
Loss for the period -23.4 -56.6 -152.7 -174.5 -231.5
Loss per share, before and after dilution (SEK) -0.26 -0.76 -1.70 -2.33 -3.02
Cash and cash equivalents (at the end of the period) 132.4 161.0 328.5

For further information, please contact:

Tomas Leanderson,
President and CEO
Tel: +46 (0)46 19 20 95



Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Fax: +46 (0)46 19 11 00

The report is also available at www.activebiotech.com.

Active Biotech AB Interim report January - September 2015 http://hugin.info/1002/R/1964749/717166.pdf

HUG#1964749

Source: Active Biotech